vs
Amphastar Pharmaceuticals, Inc.（AMPH）与DigitalOcean Holdings, Inc.（DOCN）财务数据对比。点击上方公司名可切换其他公司
DigitalOcean Holdings, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.3倍（$242.4M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 10.6%，领先2.8%），DigitalOcean Holdings, Inc.同比增速更快（18.3% vs -1.8%），DigitalOcean Holdings, Inc.自由现金流更多（$31.1M vs $24.6M），过去两年DigitalOcean Holdings, Inc.的营收复合增速更高（14.5% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
AMPH vs DOCN — 直观对比
营收规模更大
DOCN
是对方的1.3倍
$183.1M
营收增速更快
DOCN
高出20.1%
-1.8%
净利率更高
AMPH
高出2.8%
10.6%
自由现金流更多
DOCN
多$6.5M
$24.6M
两年增速更快
DOCN
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $242.4M |
| 净利润 | $24.4M | $25.7M |
| 毛利率 | 46.8% | 58.7% |
| 营业利润率 | 19.4% | 16.0% |
| 净利率 | 13.3% | 10.6% |
| 营收同比 | -1.8% | 18.3% |
| 净利润同比 | -35.7% | 40.5% |
| 每股收益（稀释后） | $0.51 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHDOCN
| Q4 25 | $183.1M | $242.4M | ||
| Q3 25 | $191.8M | $229.6M | ||
| Q2 25 | $174.4M | $218.7M | ||
| Q1 25 | $170.5M | $210.7M | ||
| Q4 24 | $186.5M | $204.9M | ||
| Q3 24 | $191.2M | $198.5M | ||
| Q2 24 | $182.4M | $192.5M | ||
| Q1 24 | $171.8M | $184.7M |
净利润AMPHDOCN
| Q4 25 | $24.4M | $25.7M | ||
| Q3 25 | $17.4M | $158.4M | ||
| Q2 25 | $31.0M | $37.0M | ||
| Q1 25 | $25.3M | $38.2M | ||
| Q4 24 | $38.0M | $18.3M | ||
| Q3 24 | $40.4M | $32.9M | ||
| Q2 24 | $37.9M | $19.1M | ||
| Q1 24 | $43.2M | $14.1M |
毛利率AMPHDOCN
| Q4 25 | 46.8% | 58.7% | ||
| Q3 25 | 51.4% | 59.6% | ||
| Q2 25 | 49.6% | 59.9% | ||
| Q1 25 | 50.0% | 61.4% | ||
| Q4 24 | 46.5% | 57.1% | ||
| Q3 24 | 53.3% | 60.2% | ||
| Q2 24 | 52.2% | 61.0% | ||
| Q1 24 | 52.4% | 60.7% |
营业利润率AMPHDOCN
| Q4 25 | 19.4% | 16.0% | ||
| Q3 25 | 13.2% | 19.6% | ||
| Q2 25 | 24.2% | 16.3% | ||
| Q1 25 | 21.9% | 17.9% | ||
| Q4 24 | 24.2% | 15.9% | ||
| Q3 24 | 29.8% | 12.4% | ||
| Q2 24 | 30.3% | 11.6% | ||
| Q1 24 | 27.9% | 6.2% |
净利率AMPHDOCN
| Q4 25 | 13.3% | 10.6% | ||
| Q3 25 | 9.0% | 69.0% | ||
| Q2 25 | 17.8% | 16.9% | ||
| Q1 25 | 14.8% | 18.1% | ||
| Q4 24 | 20.4% | 8.9% | ||
| Q3 24 | 21.1% | 16.6% | ||
| Q2 24 | 20.8% | 9.9% | ||
| Q1 24 | 25.1% | 7.7% |
每股收益（稀释后）AMPHDOCN
| Q4 25 | $0.51 | $0.23 | ||
| Q3 25 | $0.37 | $1.51 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $0.39 | ||
| Q4 24 | $0.74 | $0.21 | ||
| Q3 24 | $0.78 | $0.33 | ||
| Q2 24 | $0.73 | $0.20 | ||
| Q1 24 | $0.81 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $254.5M |
| 总债务越低越好 | $608.7M | $1.3B |
| 股东权益账面价值 | $788.8M | $-28.7M |
| 总资产 | $1.6B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHDOCN
| Q4 25 | $282.8M | $254.5M | ||
| Q3 25 | $276.2M | $236.6M | ||
| Q2 25 | $231.8M | $387.7M | ||
| Q1 25 | $236.9M | $360.4M | ||
| Q4 24 | $221.6M | $428.4M | ||
| Q3 24 | $250.5M | $439.9M | ||
| Q2 24 | $217.8M | $443.1M | ||
| Q1 24 | $289.6M | $419.1M |
总债务AMPHDOCN
| Q4 25 | $608.7M | $1.3B | ||
| Q3 25 | $608.6M | $1.3B | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHDOCN
| Q4 25 | $788.8M | $-28.7M | ||
| Q3 25 | $776.7M | $-69.6M | ||
| Q2 25 | $757.5M | $-175.2M | ||
| Q1 25 | $751.3M | $-210.7M | ||
| Q4 24 | $732.3M | $-203.0M | ||
| Q3 24 | $727.7M | $-211.7M | ||
| Q2 24 | $713.3M | $-253.8M | ||
| Q1 24 | $672.4M | $-286.1M |
总资产AMPHDOCN
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
负债/权益比AMPHDOCN
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $57.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $31.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 12.8% |
| 资本支出强度资本支出/营收 | 4.5% | 10.8% |
| 现金转化率经营现金流/净利润 | 1.35× | 2.23× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $180.5M |
8季度趋势，按日历期对齐
经营现金流AMPHDOCN
| Q4 25 | $32.9M | $57.3M | ||
| Q3 25 | $52.6M | $95.8M | ||
| Q2 25 | $35.6M | $92.4M | ||
| Q1 25 | $35.1M | $64.1M | ||
| Q4 24 | $29.0M | $71.3M | ||
| Q3 24 | $60.0M | $73.4M | ||
| Q2 24 | $69.1M | $71.3M | ||
| Q1 24 | $55.3M | $66.7M |
自由现金流AMPHDOCN
| Q4 25 | $24.6M | $31.1M | ||
| Q3 25 | $47.2M | $88.0M | ||
| Q2 25 | $25.0M | $59.3M | ||
| Q1 25 | $24.4M | $2.1M | ||
| Q4 24 | $16.6M | $26.1M | ||
| Q3 24 | $46.2M | $16.0M | ||
| Q2 24 | $63.1M | $39.5M | ||
| Q1 24 | $46.5M | $23.0M |
自由现金流率AMPHDOCN
| Q4 25 | 13.4% | 12.8% | ||
| Q3 25 | 24.6% | 38.3% | ||
| Q2 25 | 14.3% | 27.1% | ||
| Q1 25 | 14.3% | 1.0% | ||
| Q4 24 | 8.9% | 12.7% | ||
| Q3 24 | 24.1% | 8.1% | ||
| Q2 24 | 34.6% | 20.5% | ||
| Q1 24 | 27.1% | 12.5% |
资本支出强度AMPHDOCN
| Q4 25 | 4.5% | 10.8% | ||
| Q3 25 | 2.8% | 3.4% | ||
| Q2 25 | 6.1% | 15.2% | ||
| Q1 25 | 6.3% | 29.4% | ||
| Q4 24 | 6.7% | 22.1% | ||
| Q3 24 | 7.2% | 28.9% | ||
| Q2 24 | 3.3% | 16.6% | ||
| Q1 24 | 5.1% | 23.6% |
现金转化率AMPHDOCN
| Q4 25 | 1.35× | 2.23× | ||
| Q3 25 | 3.03× | 0.60× | ||
| Q2 25 | 1.15× | 2.50× | ||
| Q1 25 | 1.39× | 1.68× | ||
| Q4 24 | 0.76× | 3.91× | ||
| Q3 24 | 1.48× | 2.23× | ||
| Q2 24 | 1.82× | 3.73× | ||
| Q1 24 | 1.28× | 4.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
